The Association of Urine Arsenic with Prevalent and Incident Chronic Kidney Disease: Evidence from the Strong Heart Study

Epidemiology

Volumn 26, Issue 4, 2015, Pages 601-612

  Zheng, Laura Y ^a   Umans, Jason G ^b,c   Yeh, Fawn ^d   Francesconi, Kevin A ^e   Goessler, Walter ^e   Silbergeld, Ellen K ^a   Bandeen Roche, Karen ^f   Guallar, Eliseo ^f,g,h,i   Howard, Barbara V ^b,c   Weaver, Virginia M ^a,g,h   Navas Acien, Ana ^a,f,g  

^a Johns Hopkins University   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c Georgetown Howard Universities   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF GRAZ   (Austria)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

ⁱ DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARSENIC; ARSENOBETAINE; CACODYLIC ACID; GLUCOSE; METHANEARSONATE DISODIUM; METHANEARSONIC ACID; ORGANOARSENIC DERIVATIVE;

ADULT; AGED; AMERICAN INDIAN; ARSENIC URINE LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; INCIDENT CHRONIC KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENT CHRONIC KIDNEY DISEASE; PRIORITY JOURNAL; RISK FACTOR; RURAL POPULATION; UNITED STATES; URINE LEVEL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; ENVIRONMENTAL EXPOSURE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; STATISTICS AND NUMERICAL DATA; URINE;

AGED; ARIZONA; ARSENIC; ARSENICALS; CACODYLIC ACID; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; NORTH DAKOTA; OKLAHOMA; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SOUTH DAKOTA; UNITED STATES;

EID: 84939224785     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000313     Document Type: Article

References (58)

1. Hughes MF, Beck BD, Chen Y, Lewis AS, Thomas DJ. Arsenic exposure and toxicology: a historical perspective. Toxicol Sci. 2011;123:305-332.
2. FDA. Arsenic in rice. In: Administration USFaD, Washington, DC: US Food and Drug Administration; 2012.
3. I nternational Agency for Research on C. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: International Agency for Research on C; 2004.
4. Chen Y, Graziano JH, Parvez F, et al. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ. 2011;342:d2431.
5. Moon K, Guallar E, Navas-Acien A. Arsenic exposure and cardiovascular disease: an updated systematic review. Curr Atheroscler Rep. 2012;14:542-555.
6. Moon KA, Guallar E, Umans JG, et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study. Ann Intern Med. 2013;159:649-659.
7. Zakharyan RA, Wildfang E, Aposhian HV. Enzymatic methylation of arsenic compounds. Toxicol Appl Pharmacol. 1996;140:77-84.
8. Kim NH, Mason CC, Nelson RG, et al. Arsenic exposure and incidence of type 2 diabetes in Southwestern American Indians. Am J Epidemiol. 2013;177:962-969.
9. Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and type 2 diabetes: an updated systematic review of the epidemiologic evidence. Curr Diab Rep. 2013;13:831-849.
10. Maull EA, Ahsan H, Edwards J, et al. Evaluation of the association between arseniCand diabetes: a National Toxicology Program workshop review. Environ Health Perspect. 2012;120:1658-1670.
11. N aujokas MF, Anderson B, Ahsan H, et al. The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. Environ Health Perspect. 2013;121:295-302.
12. Sohel N, Vahter M, Ali M, et al. Spatial patterns of fetal loss and infant death in an arsenic-affected area in Bangladesh. Int J Health Geogr. 2010;9:53.
13. Kong AP, Xiao K, Choi KC, et al. Associations between microRNA (miR-21, 126, 155 and 221), albuminuria and heavy metals in Hong Kong Chinese adolescents. Clin Chim Acta. 2012;413:1053-1057.
14. Zheng L, Kuo CC, Fadrowski J, Agnew J, Weaver VM, Navas-Acien A. ArseniCand chronic kidney disease: A systematic review. Curr Environ Health Rep. 2014;1:192-207.
15. Chen Y, Parvez F, Liu M, et al. Association between arsenic exposure from drinking water and proteinuria: results from the Health Effects of Arsenic Longitudinal Study. Int J Epidemiol. 2011;40:828-835.
16. ZhenGly, Umans JG, Tellez-Plaza M, et al. Urine arseniCand prevalent albuminuria: evidence from a population-based study. Am J Kidney Dis. 2013;61:385-394.
17. Chen JW, Chen HY, Li WF, et al. The association between total urinary arsenic concentration and renal dysfunction in a community-based population from central Taiwan. Chemosphere. 2011;84:17-24.
18. Hsueh YM, Chung CJ, Shiue HS, et al. Urinary arsenic species and CKD in a Taiwanese population: a case-control study. Am J Kidney Dis. 2009;54:859-870.
19. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health. 2007;6:4.
20. Fowler BA, Chou SJ, Jones RL, Chen CJ. Arsenic. In: Nordberg GF, Fowler BA, Nordberg M, et al., eds. Handbook on the Toxicology of Metals. Amsterdam: Elsevier; 2007:367-443.
21. Zhang X, Cornelis R, De Kimpe J, et al. Accumulation of arsenic species in serum of patients with chronic renal disease. Clin Chem. 1996;42(8 Pt 1):1231-1237.
22. Zhang X, Cornelis R, Mees L, Vanholder R, Lameire N. Chemical speciation of arsenic in serum of uraemic patients. Analyst. 1998;123:13-17.
23. L ee ET, Welty TK, Fabsitz R, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990;132:1141-1155.
24. N avas-Acien A, Umans JG, Howard BV, et al. Urine arsenic concentrations and species excretion patterns in American Indian communities over a 10-year period: the Strong Heart Study. Environ Health Perspect. 2009;117:1428-1433.
25. L ee ET, Howard BV, Wang W, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation. 2006;113:2897-2905.
26. Scheer J, Findenig S, Goessler W, et al. Arsenic species and selected metals in human urine: validation of HPLC/ICPMS and ICPMS procedures for a long-term population-based epidemiological study. Anal Methods. 2012;4:406-413.
27. Shara NM, Wang H, Mete M, Al-Balha YR, Azalddin N, Lee ET, et al. Estimated GFR and incident cardiovascular disease events in American Indians: The Strong Heart Study. Am J Kidney Dis. 2012;60:795-803.
28. L evey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
29. N ational Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
30. G ribble MO, Howard BV, Umans JG, et al. Arsenic exposure, diabetes prevalence, and diabetes control in the Strong Heart Study. Am J Epidemiol. 2012;176:865-874.
31. A gresti A. Categorical Data Analysis. Hoboken, NJ: Wiley-Interscience; 2002.
32. Sweeney CJ, Takimoto C, Wood L, et al. A pharmacokinetiCand safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010;66:345-356.
33. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect. 2005;113:192-200.
34. Vij HS, Howell S. Improving the specific gravity adjustment method for assessing urinary concentrations of toxic substances. Am Ind Hyg Assoc J. 1998;59:375-380.
35. L ee ET, Cowan LD, Welty TK, et al. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988. The Strong Heart Study. Am J Epidemiol. 1998;147: 995-1008.
36. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc. 1999;94:496-509.
37. G insburg JM. Renal mechanism for excretion and transformation of arsenic in the dog. Am J Physiol. 1965;208:832-840.
38. De Kimpe J, Cornelis R, Mees L, Vanholder R, Verhoeven G. 74Asarsenate metabolism in Flemish Giant rabbits with renal insufficiency. J Trace Elem Med Biol. 1999;13:7-14.
39. Vaziri ND, Upham T, Barton CH. Hemodialysis clearance of arsenic. Clin Toxicol. 1980;17:451-456.
40. Yamamoto Y, Sasaki M, Oshimi K, Sugimoto K. Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia. Acta Haematol. 2009;122:52-53.
41. Palaneeswari M S, Rajan PM, Silambanan S, Jothimalar. Blood arseniCand cadmium concentrations in end-stage renal disease patients who were on maintenance haemodialysis. J Clin Diagn Res. 2013;7:809-813.
42. Zhang X, Cornelis R, De Kimpe J, Mees L, Lameire N. Speciation of arsenic in serum, urine, and dialysate of patients on continuous ambulatory peritoneal dialysis. Clin Chem. 1997;43:406-408.
43. Amann K, Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol. 2013;33:23-33.
44. Becker AM. Sickle cell nephropathy: challenging the conventional wisdom. Pediatr Nephrol. 2011;26:2099-2109.
45. de Burbure C, Buchet JP, Leroyer A, et al. Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect. 2006;114:584-590.
46. Weaver VM, Lee BK, Ahn KD, et al. Associations of lead biomarkers with renal function in Korean lead workers. Occup Environ Med. 2003;60:551-562.
47. Prabu SM, Muthumani M. Silibinin ameliorates arsenic induced nephrotoxicity by abrogation of oxidative stress, inflammation and apoptosis in rats. Mol Biol Rep. 2012;39:11201-11216.
48. T sukamoto H, Parker HR, Gribble DH, Mariassy A, Peoples SA. Nephrotoxicity of sodium arsenate in dogs. Am J Vet Res. 1983;44: 2324-2330.
49. PerazAma, Carter DE, Gandolfi AJ. Toxicity and metabolism of subcytotoxic inorganic arsenic in human renal proximal tubule epithelial cells (HK-2). Cell Biol Toxicol. 2003;19:253-264.
50. E scudero-Lourdes C, Medeiros MK, Cárdenas-González MC, Wnek SM, Gandolfi JA. Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model. Toxicol Appl Pharmacol. 2010;244:162-173.
51. A l GI, Khoo NK, Knaus UG, et al. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med. 2011;51:1271-1288.
52. Wang X, Zhao H, Shao Y, et al. Nephroprotective effect of astaxanthin against trivalent inorganic arsenic-induced renal injury in wistar rats. Nutr Res Pract. 2014;8:46-53.
53. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci. 2008;53:32-36.
54. Smith AH, Marshall G, Liaw J, Yuan Y, Ferreccio C, Steinmaus C. Mortality in young adults following in utero and childhood exposure to arsenic in drinking water. Environ Health Perspect. 2012;120: 1527-1531.
55. C hiu HF, Yang CY. Decreasing trend in renal disease mortality after cessation from arsenic exposure in a previous arseniasisendemic area in southwestern Taiwan. J Toxicol Environ Health A. 2005;68:319-327.
56. L ewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect. 1999;107:359-365.
57. Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol. 2007;18:2749-2757.
58. C oronado-González JA, Del Razo LM, Garciá-Vargas G, Sanmiguel-Salazar F, Escobedo-de la Penã J. Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ Res. 2007;104:383-389.